Clinical stage biotech firm Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced on Tuesday that it has been granted new patents for CM-101, its pioneering monoclonal antibody addressing fibro-inflammatory diseases. The Brazilian and Israeli patents provide additional protections for CM-101's composition and use in liver-related fibrotic diseases, including primary sclerosing cholangitis (PSC).

CM-101 is currently in Phase 2 SPRING trial, with patient enrollment completed and topline data expected in mid-2024. The unique dual mechanism of action distinguishes CM-101 from other PSC treatments, showing promise in inhibiting fibrogenesis and impacting core PSC pathways.

The Brazilian patent, published on 2 January 2024, covers CM-101 broadly for fibrotic, inflammatory and autoimmune diseases, with a first-to-expire claim in 2035. The Israeli patent, granted on 2 February 2024, focuses on CM-101's use in hepatic diseases, extending protections until 2038. Combined with existing global patents, these additions are set to safeguard CM-101 across indications. CM-101, granted Orphan Drug designation in the US and the EU, has also received Fast Track designation from the FDA for PSC treatment in adults. The Phase 2 PSC trial aims to address a critical medical need in the absence of FDA-approved therapies for this potentially lethal condition.

Chemomab is advancing CM-101's development with positive results in Phase 2a liver fibrosis trials and investigator-initiated studies, positioning it as a potential treatment for various severe fibro-inflammatory diseases. The company anticipates significant market protection until 2038, with potential extensions upon market approval.